Abstracts tagged "Qualitative Research"

Abstract Number: 1261 • ACR Convergence 2025
Use of telemedicine to address ‘off target’ symptoms in psoriatic arthritis (PsA): implementation of PsOWell™ in PsA
Carter Pason¹, Sarah Hopkins Gillespie¹, Joelle Koplin², Rachael Hewitt³, Christine Bundy³, Ethan Craig⁴, Laura Coates⁵, Jessica A. Walsh⁶ and Alexis Ogdie⁷, ¹University of Pennsylvania, Philadelphia, PA, ²Penn Medicine, Philadelphia, PA, ³University of Cardiff, Cardiff, United Kingdom, ⁴University of Pennsylvania, Wallingford, PA, ⁵Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ⁶Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ⁷Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE
Background/Purpose: Approximately 60-70% of patients with PsA do not reach minimal disease activity (MDA) on therapy. However, in many cases, this may not be related…
Abstract Number: 2619 • ACR Convergence 2025
What Works? A Consolidated Framework for Implementation Research-Guided Exploration of Patient Safety in Rheumatology Practices
Catherine Nasrallah¹, Cherish Wilson², Christine Hariz³, Alicia Hamblin⁴, Cammie Young⁵, gabriela Schmajuk⁶ and Jinoos Yazdany⁴, ¹University of California San Francisco (UCSF), San Francisco, CA, ²UCSF / SFVA, San Francisco, CA, ³University of California San Francisco (UCSF, San Francisco, CA, ⁴UCSF, San Francisco, CA, ⁵University of California, San Francisco, Oakland, CA, ⁶University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA
Background/Purpose: Despite widespread recognition of persistent patient safety challenges in the U.S. health care system, the development of feasible and scalable solutions has lagged, particularly…
Abstract Number: 1257 • ACR Convergence 2025
Integrated Behavioral Health Services for Patients with Rheumatic Diseases: Qualitative Analysis of a Pilot Study
Shannon Teaw¹, Jessica Link-Malcolm², Michelle Ghebranious Farag³, Dorothy Patterson², Jenny Foster⁴, Sofia Bereket², Puneet Bajaj², Urooj Wahid², Elizabeth Solow², Jennifer Barton⁵ and Una Makris⁶, ¹UT Southwestern Medical School, Dallas, TX, ²UT Southwestern Medical Center, Dallas, TX, ³McGovern Medical School at UT Houston, Houston, TX, ⁴UT Southwestern Medical Center, Dallas, ⁵VA Portland Health Care System/OHSU, Portland, OR, ⁶UT Southwestern Medical Center and Dallas VA, Dallas, TX
Background/Purpose: Rheumatic diseases (RD) often cause pain, fatigue and disability. Depression and anxiety are prevalent comorbidities in RD and ideally managed with behavioral health (BH)…
Abstract Number: 2603 • ACR Convergence 2025
Evaluating the Feasibility, Acceptability, and Behavioral Impact of Brief Action Planning (BAP) Coaching for Physical Activity in Adults with Chronic Knee Symptoms: A Qualitative Study
Moath Alshahrani¹, Kristin Haglund², Miranda McIlheran², Rowland Chang³, Pamela Semanik⁴, Sheikh Iqbal Ahamed² and Daniel Pinto⁵, ¹Marquette University/ King Khalid University, Milwaukee, WI, ²Marquette University, Milwaukee, WI, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Rush uUniversity, Chicago, IL, ⁵Marquette University, Wauwatosa, WI
Background/Purpose: Physical activity (PA) improves chronic knee symptoms (CKS) by decreasing pain and improving function, yet many interventions to increase PA are resource-intensive or poorly…
Abstract Number: 1050 • ACR Convergence 2025
Bridging the Gap: A Mixed-Methods Study to Enhance Integration of HCQ-SAFE, A Shared Decision-Making Tool for Hydroxychloroquine Use, in Routine Lupus Care
Isabella Hartel¹, Jay Patel¹, David Gazeley², Drake Johnson¹, Justin Levinson¹, Carmen Campbell¹, Britney Youngchild³, Shelby Gomez³, Amannda Weber⁴, Jessica Michaud⁵, Laura Dickmann⁶, Sancia Ferguson⁷, Betty Chewning⁸, Christie Bartels⁹ and Shivani Garg¹⁰, ¹University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, ²Medical College of Wisconsin, Milwaukee, WI, ³University of Wisconsin, School of Pharmacy, Madison, WI, ⁴University of Wisconsin (UW), UW Health, Madison, WI, ⁵Medical College of Wisconsin, Milwaukee, Madison, WI, ⁶Medical College of Wisconsin, Milwaukee, Milwaukee, ⁷University of Wisconsin School of Medicine and Public Health, Madison, Madison, WI, ⁸University of Wisconsin, School of Pharmacy, Madison, ⁹University of Wisconsin School of Medicine and Public Health, Madison, WI, ¹⁰University of Madison, School of Medicine and Public Health, Madison, WI
Background/Purpose: Hydroxychloroquine (HCQ) is a key therapy for lupus (or SLE). Yet, challenged to weigh benefits vs. harms, ~80% of patients self-discontinue HCQ. Shared decision-making…
Abstract Number: 2556 • ACR Convergence 2025
Information Needs of Patients with Vasculitis
Jodi Hall, Vasculitis Foundation, Shawnee, KS
Background/Purpose: The aim of this research was to discover and characterize the information needs of patients who have been diagnosed with vasculitis. Vasculitis is a term…
Abstract Number: 1506 • ACR Convergence 2025
Perspectives on Clinical Trial Participation for Novel Advanced Therapies: A Focus Group Study in Systemic Lupus Erythematosus (SLE)
Olivia A. Stein¹, Jennifer Lee¹, Evelyne Vinet², Arielle Mendel³, Christian Pineau⁴, Leanne Mielczarek⁵ and Sasha Bernatsky², ¹Research Institute of the McGill University Health Centre, Montreal, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³McGill University Health Centre, Montreal, Canada, ⁴McGill University, Montréal, QC, Canada, ⁵Lupus Canada, Newmarket, Canada
Background/Purpose: Our objective is to identify barriers and facilitators perceived by people with systemic lupus erythematosus (SLE) regarding participation in clinical trials for novel/advanced agents,…
Abstract Number: 2409 • ACR Convergence 2025
Cutaneous Lupus Activity Investigator’s Global Assessment―Revised (CLA-IGA-R) Content Validity: Cutaneous Lupus Erythematosus (CLE) Patient Qualitative Study
Joseph F Merola¹, Weihong Yang², Qianyun Li², Helen Doll³, Jason Randall³, Catherine Barbey⁴ and Feng Zeng², ¹Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ²Biogen, Cambridge, MA, ³Clinical Outcomes Solutions, Folkestone, Kent, United Kingdom, ⁴Biogen, Baar, Switzerland
Background/Purpose: The Cutaneous Lupus Activity Investigator’s Global Assessment-Revised (CLA-IGA-R) is an emerging clinician-reported outcome measure for severity of Cutaneous Lupus Erythematosus (CLE) disease activity, developed…
Abstract Number: 0794 • ACR Convergence 2025
Using Artificial Intelligence to Analyze Multilingual Qualitative Data in Lupus Pregnancy Research: A Proof of Concept with Large Language Models
Romina Boers¹, Grace Terry² and Bella Mehta³, ¹Weil Cornell Medicine, New York, ²Weil Cornell Medicine, Ne wYork, ³Hospital for Special Surgery, Weill Cornell Medicine, Jersey City, NJ
Background/Purpose: Women with systemic lupus erythematosus (SLE), particularly those of childbearing age, face heightened risks during pregnancy, including disease flares, adverse maternal-fetal outcomes, and emotional…
Abstract Number: 2204 • ACR Convergence 2025
A Novel Framework for Teratogenicity Counseling for Adolescents and Young Adults (AYAs) with Rheumatic Disease on Teratogenic Medications
Brittany Huynh¹, Elizabeth Pfeiffer² and Stacey Tarvin³, ¹Indiana University School of Medicine, Fishers, IN, ²Rhode Island College, Providence, RI, ³Riley Hospital for Children at Indiana University, Indianapolis, IN
Background/Purpose: Prior studies demonstrate low levels of knowledge and reported counseling regarding teratogenicity among AYAs with rheumatic disease. The aim of this study was to…
Abstract Number: 0520 • ACR Convergence 2025
Implementation of Salivary Gland Ultrasound by General Radiology can Improve Detection of Glandular Inflammation in Patients with Sicca
Stephanie Lee¹, Chadwick Johr², Nora Sandorfi², Ali Dhanaliwala² and Dana DiRenzo², ¹University of Pennsylvania & Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA
Background/Purpose: Salivary Gland Ultrasound (SGUS) can be useful in the evaluation and management of Sjögren’s Disease (SjD) but its use has been limited to trained…
Abstract Number: 0195 • ACR Convergence 2024
Screening for Social Determinants of Health in Patients with SLE: A Point-of-Care Feasibility Study
S. Sam Lim¹, Vijay R. Nadipelli², Michelle Bruno³, Daphne Lew⁴, Bernard Rubin⁵, Charmayne M. Dunlop-Thomas⁶, Kristi R. Mitchell³, Lydia Demetriou⁷, Jeffrey Berko³ and Alfred Kim⁸, ¹Emory University, Atlanta, GA, ²GSK, Medical Evidence Generation, Philadelphia, PA, ³Atlas Clarity, LLC, San Francisco, CA, ⁴Center for Biostatistics and Data Science, Institute for Informatics, Data Science, and Biostatistics, Washington University School of Medicine and Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO, ⁵Progentec Diagnostics, Inc., Oklahoma City, OK, ⁶Emory University School of Medicine, Department of Medicine, Division of Rheumatology, Atlanta, GA, ⁷GSK, Global Clinical Operations, Brentford, United Kingdom, ⁸Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO
Background/Purpose: Currently, social determinants of health (SDoH; conditions in which people live) are not routinely screened for in US outpatient rheumatology clinics.1 SLE disproportionally affects…
Abstract Number: 1318 • ACR Convergence 2024
Patient Anxiety, Fear, and Kinesiophobia: Challenges Shared by UK Physiotherapists in Managing Polymyalgia Rheumatica – Findings from a Qualitative Study
Anne O'Brien¹, Sara Muller¹, Jennifer Liddle², Martin Thomas¹ and Christian D Mallen³, ¹Keele University, Keele, Staffordshire, England, United Kingdom, ²Newcastle University, Newcastle upon Tyne, United Kingdom, ³Keele University, Keele, Staffordshire, United Kingdom
Background/Purpose: Polymyalgia Rheumatica (PMR) is the commonest rheumatic condition affecting older people. 35% of newly diagnosed patients report anxiety, (Muller et al., 2016) which, with…
Abstract Number: 0210 • ACR Convergence 2024
Rheumatology, Heal Thyself: The Experience of Underrepresented Physicians in Rheumatology
Rob Valdovinos¹, Ashley Martin², Jay Mehta² and Irene Blanco³, ¹UCSF Benioff Children's Hospital, San Francisco, CA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Northwestern University, Oak Park, IL
Background/Purpose: Providing racially and ethnically concordant care in minoritized populations by providers identifying as underrepresented in medicine (URiM) has been reported to be associated with…
Abstract Number: 1721 • ACR Convergence 2024
Recombinant Zoster Vaccine Uptake in US Adults with Rheumatic Disease: A Mixed Methods Analysis
Justin Gatwood¹, Catherine McGuiness², Marie Yasuda², Chi-Chang Chen², Vasudha Gupta³ and Nikita Stempniewicz¹, ¹GSK, Philadelphia, PA, ²IQVIA, Wayne, PA, ³IQVIA, Durham, NC
Background/Purpose: Compared to the immunocompetent US population ≥50 years, adults with rheumatic diseases are at increased risk for herpes zoster (HZ). To address this risk,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].